

19 **TABLE S1.** Antifungal susceptibility profiles of the clinical isolates belonging to the *Candida*
 20 *haemulonii* species complex to different azole agents.

Isolates	MIC (mg/L) ^a				
	FLC	ITC	VRC	PSC	KTC
<i>C. haemulonii</i> complex					
<i>C. haemulonii</i>					
LIPCh2	>64 (R)	1 (R)	0.5 (S)	8 (R)	4
LIPCh3	>64 (R)	>16 (R)	16 (R)	>16 (R)	2
LIPCh4	>64 (R)	>16 (R)	>16 (R)	8 (R)	2
LIPCh7	>64 (R)	16 (R)	16 (R)	0.125 (R)	0.5
LIPCh12	>64 (R)	16 (R)	16 (R)	0.5 (R)	2
<i>C. duobushaemulonii</i>					
LIPCh1	>64 (R)	8 (R)	>16 (R)	0.03 (S)	1
LIPCh6	64 (R)	0.5 (S-DD)	1 (S)	1 (R)	4
LIPCh8	>64 (R)	8 (R)	>16 (R)	>16 (R)	>16
LIPCh10	>64 (R)	0.25 (S-DD)	0.25 (S)	0.5 (R)	2
<i>C. haemulonii</i> var. <i>vulnera</i>					
LIPCh5	64 (R)	0.5 (S-DD)	0.5 (S)	0.03 (S)	0.125
LIPCh9	64 (R)	8 (R)	16 (R)	0.25 (R)	0.5
LIPCh11	>64 (R)	16 (R)	>16 (R)	0.03 (S)	1

21 ^a MIC, minimal inhibitory concentration; FLC, fluconazole; ITC, itraconazole, VRC,
 22 voriconazole; PSC, posaconazole; KTC, ketoconazole. R, resistant; S-DD, susceptible-dose
 23 dependent; S, susceptible. The clinical breakpoints defined for *Candida* spp. were used for
 24 the interpretation of MIC data as a follows: susceptible (S) ≤8 mg/L, susceptible-dose
 25 dependent (S-DD) 16-32 mg/L, resistant (R) ≥64 mg/L for FLC; S ≤0.125 mg/L, S-DD
 26 0.25-0.5 mg/L, R ≥1 mg/L for ITC; S ≤1 mg/L, S-DD 2 mg/L, R ≥4 mg/L for VRC. For PSC,
 27 the susceptibility breakpoint was considered 0.06 mg/L, determined by EUCAST for
 28 *Candida* spp. No interpretive criteria for ketoconazole are available in the CLSI or EUCAST
 29 documents.

30

31
32**Table S2. Antifungal susceptibility profiles of the non-*albicans* *Candida* species to different azole agents.**

<i>Candida</i> species	MIC (mg/L) ^a				
	FLC	ITC	VRC	PSC	KTC
<i>C. tropicalis</i> (ATCC 750)	0.5 (S)	0.03 (S)	0.03 (S)	0.03 (S)	0.03
<i>C. krusei</i> (ATCC 6258)	>64 (R)	1 (R)	0.5 (S)	0.25 (S)	0.125
<i>C. lusitanae</i> (ATCC 200950)	1 (S)	0.06 (S)	0.06 (S)	0.06 (S)	0.03

33
34
35

^a MIC, minimal inhibitory concentration; FLC, fluconazole; ITC, itraconazole, VRC, voriconazole; PSC, posaconazole; KTC, ketaconazole. R, resistant; S-DD, susceptible-dose dependent; S, susceptible.

36
37
38**TABLE S3. Homology search results comparing *Candida albicans* (SC5314) and *Candida haemulonii* (B11899) genes via BLAST.**

<i>C. albicans</i> (SC5314) genes	GenBank nucleotide accession number	<i>C. haemulonii</i> (B11899) genes	GenBank nucleotide accession number	Identity (%)	E value
<i>CDR1</i>	XM_718116.2	<i>ChCDR1</i>	XM_025483931.1	76.61	3×10^{-137}
<i>CDR2</i>	XM_718076.2	<i>ChCDR2</i>	XM_025488660.1	74.58	8×10^{-81}
<i>MDR1</i>	XM_714072.2	<i>ChMDR1</i>	XM_025484012.1	73.84	3×10^{-20}
<i>ERG11</i>	XM_711668.2	<i>ChERG11</i>	XM_025486744.1	69.38	3×10^{-163}

39